Welcome to NeoStem, Inc.

Exciting Updates to Neostem.com
As you know, NeoStem has undergone positive transformations this past year. The acquisition of Progenitor Cell Therapy (PCT) and Amorcyte furthers our progress in clinical development significantly. We have updated our website to reflect this change with a wealth of information about our own cell therapeutics. We continue to seek...
My Letter to NeoStem’s Shareholders: A Look Back at 2011 and Looking Forward
Earlier today I sent the following letter to our shareholders. Dear NeoStem Shareholders, We would like to take a moment to both look back at 2011 – a transformative year for NeoStem (NYSE Amex: NBS) – and to look ahead to near term catalysts that we expect to move the...
Building NeoStem’s Leadership in the Pharmaceutical Industry
As we continue to take on a leadership role in the development of cell therapies, the commercialization of our products, whether alone or in partnership with large pharmaceutical companies, will be integral to our strategy. We are always looking out for additional leadership to join our team with relevant experience,...

May 11, 2012
NeoStem Reports First Quarter 2012 Results and Provides Business Update
April 18, 2012
NeoStem to Present at BioCentury Future Leaders in the Biotech Industry Conference
April 11, 2012
NeoStem Announces the Addition of Jonathan Sackner-Bernstein, MD, Past FDA Official, as Vice President, Clinical Development and Regulatory Affairs
April 5, 2012
NeoStem Closes Public Offering for $6,800,000 in Gross Proceeds
March 29, 2012
NeoStem Announces Pricing of Public Offering for $6,000,000 in Gross Proceeds

Welcome to NeoStem, Inc.

NeoStem is a leader in the development and manufacture of cellular therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company.

For more information on Progenitor Cell Therapy, please visit the PCT website, www.pctcelltherapy.com.

NeoStem is the winner of The New Economy’s 2010 Biotech Award for “Best Stem Cell Company”.


Connect: